Acquisition leverage Hometa recently acquired the commercial assets of its sister company PiSA BioPharm, signaling a strategy to fill customer gaps and accelerate market penetration in infusion care. Leverage this momentum to upsell integrated infusion solutions and bundled service offerings to existing customers.

Infusion care focus Specialization in infusion care positions Hometa as a targeted partner for hospitals, clinics, and home care providers seeking precision medical devices. Sales can target procurement managers looking to consolidate infusion-related equipment and consumables under a single vendor.

Revenue opportunity With current revenue under one million, there is room for expansion through expanded product adoption, after-sales services, and geographic rollout. Focus on small-to-mid-size health systems that are building out infusion programs and may be underserved by larger device vendors.

Asset-backed growth The June 2020 asset acquisition provides a material talking point for portfolio expansion and reliability. Position Hometa as a growing, asset-backed supplier capable of delivering continuity of supply for infusion care needs during supplier transitions.

Collaborative potential The link to PiSA BioPharm suggests potential partnerships or OEM opportunities. Explore co-development or white-label arrangements with adjacent biotech or device firms to broaden product capabilities and access new customer segments.